Pacific Biosciences of Ca... (PACB)

Pacific Biosciences of California (PACB) closed at $1.18 in the latest trading session, marking a +1.72% move from the prior day.

PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth.

Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide.

PacBio and Chulalongkorn University launch Asia Pacific's first population-scale HiFi WGS newborn screening program, advancing precision medicine in Thailand.

Despite strong Service and other revenues, PACB reports soft first-quarter 2025 results partly due to lower Revio system shipments.

While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metri...

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance & Investor Relations Christ...

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.26 per share a year ago.

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.11, marking a -1.77% move from the previous day.